The estimated Net Worth of Joshua F. Patterson is at least $13.9 Тысяча dollars as of 22 September 2020. Mr Patterson owns over 319 units of Gamida Cell Ltd stock worth over $868 and over the last 5 years he sold GMDA stock worth over $13,007.
Mr has made over 3 trades of the Gamida Cell Ltd stock since 2020, according to the Form 4 filled with the SEC. Most recently he sold 319 units of GMDA stock worth $5,780 on 22 September 2020.
The largest trade he's ever made was selling 335 units of Gamida Cell Ltd stock on 23 March 2020 worth over $3,940. On average, Mr trades about 102 units every 20 days since 2020. As of 22 September 2020 he still owns at least 26,532 units of Gamida Cell Ltd stock.
You can see the complete history of Mr Patterson stock trades at the bottom of the page.
Joshua F. Patterson is the Gen. Counsel at Gamida Cell Ltd.
Mr Patterson is 45, he's been the Gen. Counsel of Gamida Cell Ltd since . There are 19 older and 1 younger executives at Gamida Cell Ltd. The oldest executive at Gamida Cell Ltd is Dr. Julian Adams Ph.D., 66, who is the CEO & Director.
Joshua's mailing address filed with the SEC is C/O GAMIDA CELL LTD., 116 HUNTINGTON AVENUE, BOSTON, MA, 02116.
Over the last 3 years, insiders at Gamida Cell Ltd have traded over $0 worth of Gamida Cell Ltd stock and bought 85,483 units worth $132,499 . The most active insiders traders include Stephen T Wills, Robert I Blum и Jeremy Blank. On average, Gamida Cell Ltd executives and independent directors trade stock every 0 days with the average trade being worth of $699. The most recent stock trade was executed by Stephen T Wills on 30 September 2022, trading 9,677 units of GMDA stock currently worth $14,999.
gamida cell is a leader in cellular and immune therapeutics, committed to changing the treatment paradigm for patients with cancer and rare genetic diseases. we are building a broad pipeline based on our proprietary nam technology platform. our lead program, nicord, is in phase 3 development for allogeneic bone marrow transplantation and was granted breakthrough therapy designation by the fda.
Gamida Cell Ltd executives and other stock owners filed with the SEC include: